Research programme: ocular therapeutics - Novaliq

Drug Profile

Research programme: ocular therapeutics - Novaliq

Alternative Names: Nov-03; Nov-04; Nov-05; Nov-07

Latest Information Update: 18 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novaliq
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Dry eyes; Glaucoma
  • Research Retinal disorders

Most Recent Events

  • 08 May 2017 Novaliq in collaboration with the University of Cologne intends to initiate a phase I trial in Dry eye in Germany
  • 13 Oct 2016 Research programme: ocular therapeutics - Novaliq is available for licensing as of 13 Oct 2016.
  • 12 Oct 2016 Early research in Retinal disorders in Germany (unspecified route) (Novaliq pipeline, October 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top